Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database-Reference-Cited by-同舟云学术

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

Published:2010-11-23 Issue:3 Volume:108 Page:378-385
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Antonarakis Emmanuel S.,Chen Yongmei,Elsamanoudi Sally I.,Brassell Stephen A.,Da Rocha Mario V.,Eisenberger Mario A.,McLeod David G.

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09878.x/fullpdf

Reference31 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

3. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus;Boccon-Gibod;Int J Clin Pract,2004

4. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy;Sandler;J Urol,2007

5. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy;Messing;Lancet Oncol,2006

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy;Journal of Urology;2024-04

2. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy;Journal of Urology;2024-04

3. Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study;Prostate International;2023-12

4. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial;European Urology;2023-03

5. Time without PSA recurrence after radical prostatectomy as a predictor of future biochemical recurrence, metastatic disease and prostate cancer death: a prospective Scandinavian cohort study;BMJ Open;2022-12